Description

Glaukos Corporation: Advancement of iDose TR & Market Penetration As  A Pivotal Growth Lever! 

Glaukos Corporation’s third quarter 2024 financial results highlighted a period of notable growth driven by strategic product developments and an expanding market presence. The company achieved record consolidated net sales of $96.7 million, representing a 24% increase from the previous year. This performance prompted Glaukos to revise its full-year 2024 net sales guidance upwards to $377 million to $379 million, reflecting optimism about continued growth.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!